Emil Kakkis, Ultragenyx CEO
January 9, 2024 02:29 AM ESTUpdated 10:59 AM
Financing
Cell/Gene Tx

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

Kyle LaHucik

Senior Reporter

SAN FRAN­CIS­CO — Ul­tragenyx, the com­mer­cial-stage Cal­i­for­nia biotech work­ing on ul­tra-rare dis­eases, is fin­ish­ing up a $50 mil­lion Se­ries A fundraise for its Alzheimer’s gene …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times